20.83

1.02% 0.21

After Hours: 20.83

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $20.83, with a volume of 1.15M. It is up +1.02% in the last 24 hours and down -5.92% over the past month. Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Previous Close:

$20.62

Open:

$20.47

24h Volume:

1.15M

Relative Volume:

0.57

Market Cap:

$2.36B

Revenue:

$6.94M

Net Income/Loss:

$-212.39M

P/E Ratio:

-8.5791

EPS:

-2.428

Net Cash Flow:

$-200.60M

1W Performance:

-0.76%

1M Performance:

-5.92%

6M Performance:

+121.83%

1Y Performance:

+143.06%

1-Day Range:

$20.02

$20.98

1-Week Range:

$19.81

$21.40

52-Week Range:

$5.1501

$27.65

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1114)

Industry

Biotechnology (621)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

177

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	20.83	2.33B	6.94M	-212.39M	-200.60M	-2.428
VRTX Vertex Pharmaceuticals Inc	458.05	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	737.45	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.50	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.10	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.72	31.33B	5.36B	287.73M	924.18M	2.5229

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Initiated	H.C. Wainwright	Buy
Dec-01-25	Initiated	Truist	Buy
Sep-22-25	Initiated	Goldman	Buy
Sep-05-25	Initiated	Craig Hallum	Buy
Apr-02-25	Initiated	Lake Street	Buy
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

01:04 AM

Behavioral Patterns of IMNM and Institutional Flows - Stock Traders Daily

01:04 AM

Mar 18, 2026

HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN

Mar 18, 2026

This Sezzle analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN

Mar 18, 2026

Mar 17, 2026

Stephens & Co. Maintains Immunome (IMNM) Overweight Recommendation - MSN

Mar 17, 2026

Immunome Inc Stock (ISIN: US45254C1062) Eyes Upside as Lock-Up Expires Today Amid Short-Term Buy Sig - AD HOC NEWS

Mar 17, 2026

Mar 16, 2026

Forecast Cut: What is the long term forecast for Immunome Inc stockBond Market & Fast Gain Stock Trading Tips - baoquankhu1.vn

Mar 16, 2026

Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com

Mar 16, 2026

Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com

Mar 16, 2026

Mar 15, 2026

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - AOL.com

Mar 15, 2026

Mar 14, 2026

Pivotal bioVenture Partners Investment Advisor LLC Invests $5.88 Million in Immunome, Inc. $IMNM - MarketBeat

Mar 14, 2026

Mar 13, 2026

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com

Mar 13, 2026

Mar 12, 2026

Loss Report: Is Immunome Inc forming a breakout pattern2026 Risk Factors & Weekly Stock Breakout Alerts - baoquankhu1.vn

Mar 12, 2026

Bienaime buys Immunome (IMNM) shares worth $43,670 By Investing.com - Investing.com UK

Mar 12, 2026

Immunome (IMNM) director buys 2,000 shares in open market - Stock Titan

Mar 12, 2026

Mar 11, 2026

Craig-Hallum Initiates Coverage of Immunome (IMNM) with Buy Recommendation - MSN

Mar 11, 2026

A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration - simplywall.st

Mar 11, 2026

Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha

Mar 11, 2026

Immunome (IMNM) to Release Earnings on Wednesday - MarketBeat

Mar 11, 2026

Mar 08, 2026

(IMNM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 08, 2026

Mar 07, 2026

Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to "Sell" - MarketBeat

Mar 07, 2026

Is Immunome Inc forming a breakout patternJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn

Mar 07, 2026

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Immunome (IMNM) - The Globe and Mail

Mar 07, 2026

Mar 06, 2026

Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - finance.yahoo.com

Mar 06, 2026

Whale Trades: How do insiders feel about Immunome IncMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn

Mar 06, 2026

HC Wainwright Brokers Raise Earnings Estimates for Immunome - MarketBeat

Mar 06, 2026

Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - Sahm

Mar 06, 2026

Mar 05, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com

Mar 05, 2026

HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat

Mar 05, 2026

Mar 04, 2026

IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus

Mar 04, 2026

Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus

Mar 04, 2026

Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat

Mar 04, 2026

Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat

Mar 04, 2026

Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus

Mar 04, 2026

Mar 03, 2026

Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus

Mar 03, 2026

Immunome 2025 Net Loss Narrows - marketscreener.com

Mar 03, 2026

Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus

Mar 03, 2026

Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com

Mar 03, 2026

Immunome: Q4 Earnings Insights - Benzinga

Mar 03, 2026

IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView

Mar 03, 2026

Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 03, 2026

Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan

Mar 03, 2026

Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan

Mar 03, 2026

Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire

Mar 03, 2026

TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat

Mar 03, 2026

IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Mar 02, 2026

How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st

Mar 02, 2026